Meeting
2011 ASCO Annual Meeting
A phase II randomized study of lenalidomide or lenalidomide and rituximab as maintenance therapy following standard chemotherapy for patients with high/high-intermediate risk diffuse large B-cell lymphoma.
Authors
N. M. Reddy
Vanderbilt University Medical Center, Nashville, TN
N. M. Reddy , R. Simmons , M. Caldwell , M. H. Jagasia , D. S. Morgan , S. I. Park , J. P. Greer , K. L. Richards
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session
Track
Special Sessions,Clinical Trials
Sub Track
Clinical Trial Design
Clinical Trial Registration Number
NCT00765245
Citation
J Clin Oncol 29: 2011 (suppl; abstr TPS138)
Abstract #
TPS138
Poster Bd #
40H
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
First-line treatment (Tx) with subcutaneous (SC) epcoritamab (epco) + R-CHOP in patients (pts) with high-risk diffuse large B-cell lymphoma (DLBCL): Phase 1/2 data update.
First Author: Lorenzo Falchi
Poster
2018 ASCO Annual Meeting
Long term follow-up (FU) of lenalidomide plus R-CHOP therapy in patients with newly diagnosed diffuse large b-cell lymphoma (DLBCL): Combined analysis from two phase 2 trials.
First Author: Alessia Castellino
Poster
2016 ASCO Annual Meeting
Rituximab, lenalidomide, and ibrutinib alone and combined with dose adjusted chemotherapy for patients with high risk diffuse large B-cell lymphoma.
First Author: Jason R. Westin
Poster
2011 ASCO Annual Meeting
Randomized phase II study of R-CHOP plus enzastaurin versus R-CHOP in the first-line treatment of patients with intermediate- and high-risk diffuse large B-cell lymphoma (DLBCL): Preliminary analysis.
First Author: J. D. Hainsworth